<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Joint Progression Modeling (JPM): A Probabilistic Framework for Mixed-Pathology Progression - Health AI Hub</title>
    <meta name="description" content="This paper introduces the Joint Progression Model (JPM), a novel probabilistic framework designed to infer disease progression in individuals affected by mixed ">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Joint Progression Modeling (JPM): A Probabilistic Framework for Mixed-Pathology Progression</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.03475v1" target="_blank">2512.03475v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-03
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Hongtao Hao, Joseph L. Austerweil
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, stat.AP
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.03475v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.03475v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces the Joint Progression Model (JPM), a novel probabilistic framework designed to infer disease progression in individuals affected by mixed pathologies, a common scenario in neurodegeneration. Unlike standard Event-Based Models (EBMs) that assume a single disease, JPM treats individual disease trajectories as partial rankings and builds a prior over their joint progression. The framework demonstrates improved ordering accuracy (approximately 21% over a strong baseline) in synthetic experiments and produces results consistent with existing literature for mixed Alzheimer's Disease and Vascular Dementia progression using NACC data.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This model provides a more sophisticated and realistic approach to understanding the complex, multi-pathology progression prevalent in neurodegenerative diseases. This can lead to earlier, more accurate diagnosis and the development of personalized treatment strategies that account for the simultaneous progression of multiple conditions.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The research develops a probabilistic machine learning framework (Joint Progression Model - JPM) to infer and model the progression of mixed pathologies (multiple co-occurring diseases) from cross-sectional data. This AI application aims to improve the understanding and prediction of complex disease trajectories in conditions like Alzheimer's Disease and Vascular Dementia, which can aid in earlier diagnosis, more accurate prognosis, and potentially more targeted therapeutic interventions for patients with mixed neurodegenerative conditions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>JPM is a probabilistic framework specifically developed to model progression in mixed pathologies, addressing the limitation of single-disease assumptions in conventional Event-Based Models (EBMs).</li>
                    
                    <li>It conceptualizes single-disease trajectories as 'partial rankings' and constructs a prior distribution to infer complex 'joint progressions' of multiple co-occurring diseases.</li>
                    
                    <li>The framework evaluates several JPM variants (Pairwise, Bradley-Terry, Plackett-Luce, Mallows) based on properties like calibration, separation, and sharpness.</li>
                    
                    <li>All JPM variants exhibited strong calibration (lower energy predicts higher accuracy) and near-perfect separation (distinguishing meaningful rankings from random ones).</li>
                    
                    <li>Sharpness, indicating the stability of sampled aggregate rankings, varied among variants and was predictable by features such as the number and length of input partial rankings, as well as conflict and overlap.</li>
                    
                    <li>In synthetic experiments, JPM achieved a significant improvement in ordering accuracy, approximately 21%, over SA-EBM, a strong EBM baseline that simplifies mixed disease as a single condition.</li>
                    
                    <li>Using real-world NACC data, the Mallows variant of JPM and the SA-EBM baseline produced progression insights for mixed Alzheimer's Disease (AD) and Vascular Dementia (VaD) that were consistent with prior medical literature.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The Joint Progression Model (JPM) is a probabilistic framework that treats single-disease progression paths as partial rankings. It then constructs a prior over possible joint progressions, effectively combining these individual trajectories. The paper evaluates several JPM variants (Pairwise, Bradley-Terry, Plackett-Luce, Mallows) against properties such as calibration, separation, and sharpness. Performance is benchmarked against a strong EBM baseline (SA-EBM) using both synthetic datasets and real-world clinical data from the National Alzheimer's Coordinating Center (NACC) for analyzing AD and VaD mixed pathologies.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>['JPM variants are well-calibrated and achieve near-perfect separation, indicating their ability to infer meaningful and accurate disease progression.', 'Sharpness, or the stability of inferred aggregate rankings, is variant-dependent but can be predicted by characteristics of the input partial rankings.', 'JPM significantly improves ordering accuracy by approximately 21% compared to a baseline model (SA-EBM) that treats mixed pathology as a single condition, demonstrating its advantage in complex scenarios.', 'Application to NACC data for mixed AD and VaD revealed that the Mallows JPM variant, along with the SA-EBM baseline, produced disease progression sequences consistent with established medical literature, affirming its clinical validity.']</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This framework has the potential to enhance the precision of disease staging and prognosis for patients suffering from mixed neurodegenerative conditions, which are often clinically challenging to differentiate. By offering a granular understanding of how multiple pathologies co-evolve, JPM could facilitate more targeted, personalized therapeutic interventions and biomarker development, ultimately improving patient management and outcomes.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state limitations. However, potential implicit limitations may include the reliance on accurately defined single-disease 'partial rankings' as input, the computational demands for highly complex mixed pathologies involving many diseases, and that the 'consistency with prior literature' finding, while validating, might imply limited discovery of entirely novel progression patterns for AD/VaD.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly mention future directions. However, logical next steps would include applying JPM to a broader spectrum of mixed pathologies, integrating diverse data types (e.g., genetic, imaging, fluid biomarkers) directly into the framework, and developing more robust methods for inferring the initial 'partial rankings' from varied and potentially noisy clinical datasets.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Neurology</span>
                    
                    <span class="tag">Geriatrics</span>
                    
                    <span class="tag">Dementia Research</span>
                    
                    <span class="tag">Computational Neuroscience</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Disease progression</span>
                    
                    <span class="tag tag-keyword">Mixed pathology</span>
                    
                    <span class="tag tag-keyword">Neurodegeneration</span>
                    
                    <span class="tag tag-keyword">Event-based models</span>
                    
                    <span class="tag tag-keyword">Probabilistic framework</span>
                    
                    <span class="tag tag-keyword">Alzheimer's disease</span>
                    
                    <span class="tag tag-keyword">Vascular dementia</span>
                    
                    <span class="tag tag-keyword">Machine learning</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Event-based models (EBMs) infer disease progression from cross-sectional data, and standard EBMs assume a single underlying disease per individual. In contrast, mixed pathologies are common in neurodegeneration. We introduce the Joint Progression Model (JPM), a probabilistic framework that treats single-disease trajectories as partial rankings and builds a prior over joint progressions. We study several JPM variants (Pairwise, Bradley-Terry, Plackett-Luce, and Mallows) and analyze three properties: (i) calibration -- whether lower model energy predicts smaller distance to the ground truth ordering; (ii) separation -- the degree to which sampled rankings are distinguishable from random permutations; and (iii) sharpness -- the stability of sampled aggregate rankings. All variants are calibrated, and all achieve near-perfect separation; sharpness varies by variant and is well-predicted by simple features of the input partial rankings (number and length of rankings, conflict, and overlap). In synthetic experiments, JPM improves ordering accuracy by roughly 21 percent over a strong EBM baseline (SA-EBM) that treats the joint disease as a single condition. Finally, using NACC, we find that the Mallows variant of JPM and the baseline model (SA-EBM) have results that are more consistent with prior literature on the possible disease progression of the mixed pathology of AD and VaD.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>49 pages; Machine Learning for Health (ML4H) Symposium 2025</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>